Table 2 Circulating tumor cells and tumor derived extracellular vesicles
Biomarker | Descriptive | Median (range)/number of patients (%) |
|---|---|---|
CTC at T0 (n = 104) | Median (range) | 0 (0–141) |
Patients with CTC | 33 (32) | |
Patients with CTC > 5 | 10 (10) | |
CTC at T1 (n = 63) | Median (range) | 0 (0–85) |
Patients with CTC | 17 (27) | |
Patients with CTC > 5 | 2 (3) | |
Change in CTC (between T0 and T1) (n = 63) | Median (range) | 0 (− 8 − + 39) |
Pts with decrease | 11 (16) | |
Pts with increase | 11 (17) | |
Pts with no change | 41 (65) | |
tdEV at T0 (n = 104) | Median (range) | 6.5 (0–1753) |
Pts with tdEV≥18 | 27 (26) | |
tdEV at T1 (n = 63) | Median (range) | 5 (0–1975) |
Pts with tdEV≥18 | 11 (17) | |
Change in tdEV (between T0 and T1) (n = 63) | Median (range) | -1 (−46 − + 222) |
Pts with decrease | 33 (52) | |
Pts with increase | 29 (46) | |
Pts with no change | 1 (2) |